Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PolyPeptide Group AGPLYGF 61 3-1 Month Momentum % is -5.49% as of Jul. 26, 2026. GuruFocus rates PLYGF with a GF Score™ of 61/100 and a GF Value™ of $41.28 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,024 Drug Manufacturers companies, PolyPeptide Group AG ranks better than 87.7% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-26), PolyPeptide Group AG's 3-1 Month Momentum % is -5.49%.
The industry rank for PolyPeptide Group AG's 3-1 Month Momentum % or its related term are showing as below:
PLYGF's 3-1 Month Momentum % is ranked better than 87.7% of 1024
companies
in the Drug Manufacturers industry
Industry Median: -8.24
vs PLYGF: -5.49
PolyPeptide Group AG (OTCPK:PLYGF) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
PolyPeptide Group AG 3-1 Month Momentum % Related Terms
PLYGF vs ZTS, UTHR, VTRS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PolyPeptide Group AG 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where PolyPeptide Group AG's 3-1 Month Momentum % falls into.
PolyPeptide Group AG (OTCPK:PLYGF) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PolyPeptide Group AG (PLYGF) has a 3-1 Month Momentum % of -5.49% as of Jul. 26, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on PolyPeptide Group AG and its competitors. According to the industry distribution chart, PolyPeptide Group AG ranks #126 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 12.3%.
Is PolyPeptide Group AG's 3-1 Month Momentum % too high?
PolyPeptide Group AG's current 3-1 Month Momentum % is -5.49%. Based on the distribution chart, PolyPeptide Group AG ranks #126 out of 1024 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PolyPeptide Group AG has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's 3-1 Month Momentum % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PolyPeptide Group AG ranks #126 out of 1024 companies for 3-1 Month Momentum %. This places PolyPeptide Group AG in the top 12% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on PolyPeptide Group AG and its competitors. PolyPeptide Group AG's current 3-1 Month Momentum % is -5.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (PLYGF) is currently considered Fairly Valued. The stock's GF Value™ is $41.28, compared to a current price of $43.00 — trading 4.2% above its estimated fair value. The current 3-1 Month Momentum % is -5.49%. PolyPeptide Group AG's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For PolyPeptide Group AG (PLYGF), the current 3-1 Month Momentum % is -5.49% as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PolyPeptide Group AG (PLYGF) Overvalued in 2026?
Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued.
The current stock price of $43.00 is trading 4.2% above its estimated GF Value™ of $41.28.
GuruFocus considers PolyPeptide Group AG to be Fairly Valued.
Key valuation signals for PLYGF:
3-1 Month Momentum %: -5.49%
GF Value™: $41.28 vs. price of $43.00 (4.2% above fair value)
No single metric tells the full story. See the PLYGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
61GF Score
Get the complete analysis for PLYGF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLYGF has been successfully added to your 
